Cancer is the second leading cause of death worldwide, and treatments for cancer are constantly evolving.  Currently, although powerful, chemotherapy still suffers from side effects associated with the blocking of major biological pathways.  The Moschitto Research Group, which started in September of 2019 at Rutgers University, aims to provide additional methods for the treatment of cancers through the development of new therapeutics that combines synthetic organic chemistry, medicinal chemistry, and cancer biology.  To achieve this, we focus on the development of inhibitors that target metabolic enzymes through either irreversible or reversible means.  Additionally, we look to synthesize natural products and natural product scaffolds to obtain potent and selective therapeutics. When necessary, we will employ novel methodologies to form strategic bonds, thus improving the ease of access to important scaffolds.